Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09CZA
|
|||
| Former ID |
DAP000274
|
|||
| Drug Name |
Travoprost
|
|||
| Synonyms |
Travatan; Travatanz; Travatan Alcon; Travatan Z; Travoprost [USAN]; AL6221; AL-6221; Travatan (TN); Travatan Z (TN); Travatan, Travoprost; Travoprost (JAN/USAN/INN); Propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate; Propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate; (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester; (+)-Fluprostenol isopropyl ester; (1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-Dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester; (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3R)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate; 5-Heptenoic acid,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-,1-methylethyl ester,(5Z)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Open-angle glaucoma [ICD-11: 9C61] | Approved | [1], [2] | |
| Therapeutic Class |
Ophthalmologicals
|
|||
| Company |
Alcon Canada Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H35F3O6
|
|||
| Canonical SMILES |
CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O
|
|||
| InChI |
1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1
|
|||
| InChIKey |
MKPLKVHSHYCHOC-AHTXBMBWSA-N
|
|||
| CAS Number |
CAS 157283-68-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7849026, 7980824, 8616953, 11528776, 12015307, 14884338, 14933310, 39315701, 46507637, 57358581, 71851435, 74994240, 92722486, 99367288, 103770782, 104253208, 113856711, 124757334, 125164138, 126592911, 126618229, 126662418, 134223572, 134337588, 135692177, 137005800, 143086628, 160963635, 162181276, 174549089, 175268016, 175437848, 178103680, 179150016, 210279750, 210282073, 223660449, 224318898, 226471523, 241376872, 252157882, 252216510, 252562118
|
|||
| ChEBI ID |
CHEBI:746859
|
|||
| ADReCS Drug ID | BADD_D02265 | |||
| SuperDrug ATC ID |
S01EE04
|
|||
| SuperDrug CAS ID |
cas=157283686
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin F2-alpha receptor (PTGFR) | Target Info | Agonist | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Reactome | Prostanoid ligand receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7102). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.